(redirected from Apolipoprotein B)
Also found in: Medical, Encyclopedia, Wikipedia.
APOBApolipoprotein B
APOBArchitects and Planners of Boulder (Colorado)
APOBAmericans for the Preservation of Bail
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Bell et al., "Plasma very low density lipoproteins contain a single molecule of apolipoprotein B," Journal of Lipid Research, vol.
Danesh, "Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies," Journal of Internal Medicine, vol.
"The apolipoprotein A-1 and apolipoprotein B effects mirrored the effects of HDL and LDL."
These results show that level of apolipoprotein B, alpha-2- macroglobulin, ceruloplasmin, immunoglobulin heavy chain and 17 kDa proteins and expression of 23.5 kDa protein fractions are strong predictor of RHD and can be used for its diagnosis.
"A functional polymorphism in the apolipoprotein B promoter that influences the level of plasma low density lipoprotein," J.
Standard hospital assays (Konelab) performed at the Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, were used on fresh blood samples to measure plasma concentrations of glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, and albumin.
Genetic polymorphisms in apolipoprotein B and apo E (APO B and APO E) have been studied for association with plasma LDL cholesterol levels and of these, only APO E polymorphisms have shown consistent associations (97,128,129).
Masoud Toloue, Senior Scientist at Bioo Scientific, "Elevated plasma concentration of Apolipoprotein B (ApoB) is an established risk factor for atherosclerosis and a better indicator of heart disease than total cholesterol or LDL alone making it a highly sought after pharmaceutical lipid target.
The drug lowered serum levels of the atherogenic compounds apolipoprotein B, triglycerides, and Lp(a) lipoprotein.
The researchers found that very high HDL levels and very large HDL particles increased the risk of coronary artery disease when levels of apoA-I and apolipoprotein B (apoB, a component of LDL "bad" cholesterol) remained steady.
Baseline evaluation included measuring standard lipid levels (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein cholesterol), as well as non-HDL cholesterol, apolipoprotein A-I, and apolipoprotein B. None of the participants had cardiovascular disease at the beginning of the study.
Apolipoprotein B. Apo B is the sole protein component of LDL.